[1]马伟,石秦林,田小毛,等.淋巴结受累与取样数目对肾母细胞瘤患儿预后的影响[J].陆军军医大学学报(原第三军医大学学报),2021,43(09):858-862.MA Wei,SHI Qinlin,TIAN Xiaomao,et al.Effects of lymph node involvement and dissection number on prognosis in patients with Wilms tumor[J].J Amry Med Univ (J Third Mil Med Univ),2021,43(09):858-862.
MA Wei, SHI Qinlin, TIAN Xiaomao, et al. Effects of lymph node involvement and dissection number on prognosis in patients with Wilms tumor. [J]. Journal of Army Medical University 43(9):858-862(2021)
[1]马伟,石秦林,田小毛,等.淋巴结受累与取样数目对肾母细胞瘤患儿预后的影响[J].陆军军医大学学报(原第三军医大学学报),2021,43(09):858-862.MA Wei,SHI Qinlin,TIAN Xiaomao,et al.Effects of lymph node involvement and dissection number on prognosis in patients with Wilms tumor[J].J Amry Med Univ (J Third Mil Med Univ),2021,43(09):858-862. DOI: 10.16016/j.1000-5404.202011052.
MA Wei, SHI Qinlin, TIAN Xiaomao, et al. Effects of lymph node involvement and dissection number on prognosis in patients with Wilms tumor. [J]. Journal of Army Medical University 43(9):858-862(2021) DOI: 10.16016/j.1000-5404.202011052.
Effects of lymph node involvement and dissection number on prognosis in patients with Wilms tumor
目的探究淋巴结受累与取样数目对肾母细胞瘤患儿预后的影响。方法采用回顾性队列研究,收集2010年1月至2019年12月在重庆医科大学附属儿童医院规范化治疗的肾母细胞瘤173例患儿的临床资料。根据淋巴结是否受累及取样数量分组,采用Kaplan-Meier生存函数描述生存结局,Log-rank检验比较组间患儿的5年无事件生存率(event-free survival,EFS)的差异。Pearson χ2检验用于分类变量的比较。结果共173例患儿纳入研究,男性81例,女性92例,年龄1个月至13岁,发病中位年龄为2岁,中位随访时间53(3~108)个月。淋巴结受累与未受累患儿分别有23例(13.3%)和150例(86.7%),5年EFS分别为56.19% vs 81.27%(P<0.000 1)。淋巴结受累与未受累患儿的5年EFS在预后不良型(uFH型)患儿中分别为25.00% vs 71.13%(P<0.000 1),在预后良好型(FH型)患儿中分别为73.33% vs 84.16%(P=0.091 8)。淋巴结取样数量为1~3个、4~6个、7~9个和超过10个的患儿中,淋巴结的阳性率分别为4.23%、7.32%、38.46%和43.75%(P<0.000 1)。在Ⅰ期和Ⅱ期患儿中,淋巴结取样数量与患儿预后无显著关联(P=0.479 0)。结论淋巴结受累是肾母细胞瘤患儿的不良预后因素,特别是在uFH型患儿中;淋巴结取样数量超过7个时发现阳性淋巴结的概率更大;但淋巴结取样数量与预后无关。
Abstract
ObjectiveTo investigate the effects of lymph node involvement and dissection number on prognosis in patients with Wilms tumor (also known as nephroblastoma). MethodsClinical data of all the children with Wilms tumor who received standardized treatment in our hospital from January 2010 to December 2019 were collected and retrospectively analyzed. The patients were divided into different groups according to lymph node involvement and sampling number. The survival outcome and 5-year event-free survival (EFS) among different groups were analyzed with Kaplan-Meier survival analysis and Log-rank test
respectively. Pearson’s Chi-squared test was used to compare categorical variables among groups. ResultsA total of 173 patients (81 boys and 92 girls) were enrolled in this study
with a median follow-up of 53 (3~108) months. Among them
23 patients (13.30%) had lymph node involvement
and 150 (86.70%) had not
and the ratio of 5-year EFS was 56.19% and 81.27%
respectively (P<0.000 1). Moreover
the ratio for those with unfavorable histology (uFH) was 25.00% and 71.13% (P<0.000 1)
respectively
and that for those with favorable histology (FH) was 73.33% and 84.16%
respectively in the patients with or without lymph node involvement (P=0.091 8). For the patients with dissected lymph node number of 1~3
4~6
7~9 and >10
the rate of positive lymph node was 4.23%
7.32%
38.46% and 43.75%
respectively (P<0.000 1). There was no significant correction between the dissection number and prognosis in the stage Ⅰ and stage Ⅱ patients (P=0.479 0). ConclusionLymph node involvement is a poor prognostic factor in patients with Wilms tumor
especially in those with uFH. The probability of detecting positive lymph node is higher when the number of dissected node larger than 7
but the dissection number has no effect on prognosis.
Long-term effect of ureteroscopy prior to radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis
Expression and clinical significance of phosphorylated FGFR1Y654 in esophageal squamous cell carcinoma
Prognostic value of albumin in patients with de novo non-M3 acute myeloid leukemia
Prognostic factors for breast cancer brain metastasis and primary construction of a prediction model
Related Author
Su Zhang
Cheng Wang
Zhenxing Zhai
Juan Wang
Jiping Niu
Shengjun Fu
Xinping Wang
Li Yang
Related Institution
Department of Urology, Lanzhou University Institute of Urology, Gansu Nephron-Urological Clinical Center, Gansu Provincial Key Laboratory of Urological System Diseases, Second Hospital of Lanzhou University
Department of Oncology, General Hospital of Western Theater
Faculty of Clinical Medicine, College of Medicine, Southwest Jiaotong University
Center for Hematology, First Affiliated Hospital, Army Medical University (Third Military Medical University)
Department of Breast and Thyroid Surgery, First Affiliated Hospital, Army Medical University (Third Military Medical University)